On May 14, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported data analyzing the applicability of the INTASYL platform as a gene silencing technology that offers an alternative or complementary approach to gene editing technologies, such as CRISPR / Cas9, in the treatment of solid tumors (Press release, Phio Pharmaceuticals, MAY 14, 2020, View Source [SID1234558041]). These data will be presented today at 5:30 p.m. ET at the 23rd Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) in virtual format. The Phio poster presentation will also be available under the "Investors – Events and Presentations" section of the Company’s website (click here) approximately one hour after the event.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data from the poster details how INTASYL compares favorably to other technologies for improving cells used in adoptive cell therapy (ACT) for the treatment of solid tumors, especially in cases where permanent gene modification is not required or is undesirable. The poster will be presented by Dr. Simon P. Fricker, Phio’s Vice President of Research.
"We have shown that our INTASYL technology is able to reprogram immune cells, such as T cells or NK cells, and thereby significantly improve their cell killing activity. Alternative approaches to enhancing ACT for solid tumors, such as genetic modification with CRISPR / Cas9, have their merit but also are confronted by significant shortcomings. These data presented today, and also impressive new animal data scheduled to be presented at the upcoming AACR (Free AACR Whitepaper) and ASCO (Free ASCO Whitepaper) meetings in the coming weeks, show that the INTASYL platform has great promise for the improvement of ACT therapies without the need for gene editing."
Phio’s technology is also featured on a poster from Glycostem Therapeutics BV presented at ASGCT (Free ASGCT Whitepaper) titled: "oNKord Natural Killer Cells Are Recognized As a Powerful, Versatile and Universal "Off The Shelf" Treatment to Develop Novel Genetically Modified Anti-Cancer Products" (Abstract #1152).